---
title: "Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen (2)"
ocid: "ocds-b5fd17-5b43d132-3d21-4b67-b019-1c437e7a1065"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-b5fd17-5b43d132-3d21-4b67-b019-1c437e7a1065"
markdown_url: "https://d3tenders.com/contract/ocds-b5fd17-5b43d132-3d21-4b67-b019-1c437e7a1065.md"
json_url: "https://d3tenders.com/contract/ocds-b5fd17-5b43d132-3d21-4b67-b019-1c437e7a1065.json"
source: "Contracts Finder"
current_stage: "Tender"
buyer: "NHS ARDEN AND GREATER EAST MIDLANDS COMMISSIONING SUPPORT UNIT"
published: "2020-03-05"
---

# Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen (2)

Buyer: NHS ARDEN AND GREATER EAST MIDLANDS COMMISSIONING SUPPORT UNIT  
Current stage: Tender  
OCID: ocds-b5fd17-5b43d132-3d21-4b67-b019-1c437e7a1065

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-b5fd17-5b43d132-3d21-4b67-b019-1c437e7a1065)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-b5fd17-5b43d132-3d21-4b67-b019-1c437e7a1065.json)

## Summary

The NHS Arden and Greater East Midlands Commissioning Support Unit is currently seeking providers for a tender titled "Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen." This procurement falls under the health services category and covers multiple regions across the United Kingdom, including the East Midlands, London, and North West, among others. The tender is in the active planning stage and has a closing date for submissions set for 1 April 2020, with the contract expected to commence on 1 June 2020 and run for three years, with an option for extension until the end of the Managed Access Agreement in July 2024. The procurement method is classified as "Other -," aimed at addressing service gaps for the treatment of patients with a rare genetic condition.

This tender presents significant opportunities for organisations specialising in healthcare services, particularly those experienced in treating patients with neuromuscular disorders. Providers should have the necessary infrastructure and qualifications to administer the drug Nusinersen via intrathecal injection, as well as to conduct patient monitoring effectively. Given the NHS's commitment to improving access to this treatment for approximately 600 eligible patients, businesses in the fields of healthcare, pharmaceuticals, and medical treatment services should consider participating in this tender to enhance their market presence and contribute to vital patient care.

## Notice

NHS Arden and Greater East Midlands CSU (AGCSU) on behalf of NHS England Specialised Commissioning is inviting suitably qualified and experienced providers to deliver Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen under the Compliance Process specified in Document 1 - Process Overview of process documentation. On 24 July 2019, NICE published Technology appraisal guidance on the use of the drug Nusinersen to treat patients with 5q Spinal Muscular Atrophy (SMA). This is a rare, genetic, neuromuscular disease, characterised by spinal motor neuron loss, muscle atrophy and motor impairment. SMA is debilitating for all patients and fatal for the worst affected; patients and their families can experience extremely high levels of burden. NHS England has agreed a 'Managed Access Agreement (MAA)' for the drug nusinersen for the treatment of eligible patients with spinal muscular atrophy (SMA). The NICE guidance sets out that the drug should only be made available to people who meet the criteria for treatment under the associated MAA. The key objectives of the Compliance Process are: to commission the service(s) to serve adult patients eligible to receive the treatment nationally. It is estimated that 600 patients (adults and children) will be treated in England over the lifetime of the contract. Patients' eligibility and population covered are described in section 4 of the Managed Access Agreement. This may include treating patients from the devolved nations. The Commissioner is seeking to appoint providers who have expertise in the treatment of adults with SMA (from 16-18 years of age, depending on local agreements) and who have the infrastructure both to be able to treat patients with nusinersen (which is given by intrathecal injection) and to collect detailed monitoring information about eligible patients. Providers will need to demonstrate that they are suitably qualified and can meet the agreed service requirements. In 2019, NHS England ran a compliance process to appoint providers to deliver the service and was able to appoint several suitably qualified and experienced providers. Since then, the Commissioners have assessed patients' needs and have identified service gaps nationally. In order to address these gaps, the Commissioners are re-issuing the opportunity. Further information about scope and qualification requirements can be found in the process documentation published on the EU Supply eTender/Procurement portal (Quote/tender 39295). All communications regarding this opportunity will be managed via the EU Supply messaging service. Additional information: An agreement will be established with the successful applicants for a period of 3 (three) years with the Commissioner having the option to extend the contract until the end of the Managed Access Agreement (24 July 2024). To apply please visit https://uk.eu-supply.com/login.asp?B=UK Quote/tender 39295 - NHS England Spec. Commissioning - Treatment to adult patients who have 5Q Spinal Muscular Atrophy (SMA) with the Drug Nusinersen (2).

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Contracts Finder |
| Latest notice | https://www.contractsfinder.service.gov.uk/Notice/f5119c94-5f57-4f10-ba0a-9b2869968aeb |
| Notice type | Tender Notice |
| Procurement type | Standard |
| Procurement category | Services |
| Procurement method | Not Specified |
| Procurement method details | Other - |
| Tender suitability | Not specified |
| Awardee scale | Not specified |
| All stages | Tender |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 5 Mar 2020 |
| Submission deadline | 1 Apr 2020 |
| Future notice date | Not specified |
| Award date | Not specified |
| Contract period | 31 May 2020 - 1 Jun 2023 |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | Not specified |

## Status

| Field | Value |
| --- | --- |
| Tender status | Active |
| Lots status | Not specified |
| Awards status | Not specified |
| Contracts status | Not specified |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS ARDEN AND GREATER EAST MIDLANDS COMMISSIONING SUPPORT UNIT |
| Locality | LONDON |
| Post town | South East London |
| Postcode | SE1 6LH |
| Country | England |
| ITL 1 | TLI London |
| ITL 2 | TLI4 Inner London - East |
| ITL 3 | TLI44 Lewisham and Southwark |
| Local authority | Southwark |
| Electoral ward | St George's |
| Westminster constituency | Bermondsey and Old Southwark |
| Delivery location | TLC North East (England), TLD North West (England), TLE Yorkshire and The Humber, TLF East Midlands (England), TLG West Midlands (England), TLI London, TLJ South East (England), TLK South West (England) |

## CPV Codes

### Divisions

- 85 - Health and social work services

### Codes

- 85100000 - Health services

## Release History

- 5 Mar 2020 at 17:32 - Tender - Tender Notice - https://www.contractsfinder.service.gov.uk/Notice/f5119c94-5f57-4f10-ba0a-9b2869968aeb

## Documents

- https://www.contractsfinder.service.gov.uk/Notice/f5119c94-5f57-4f10-ba0a-9b2869968aeb
  5th March 2020 - Opportunity notice on Contracts Finder

## Notice URLs

- https://uk.eu-supply.com/login.asp?B=UK
- https://www.ardengemcsu.nhs.uk/

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-b5fd17-5b43d132-3d21-4b67-b019-1c437e7a1065. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-b5fd17-5b43d132-3d21-4b67-b019-1c437e7a1065.json.